These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Paclitaxel poliglumex for ovarian cancer.
    Author: Galic VL, Wright JD, Lewin SN, Herzog TJ.
    Journal: Expert Opin Investig Drugs; 2011 Jun; 20(6):813-21. PubMed ID: 21470062.
    Abstract:
    INTRODUCTION: Despite an 80% initial response rate to the standard primary regimen of carboplatin and paclitaxel, most women with ovarian cancer will experience recurrence with incurable disease within five years and will be treated with several successive palliative regimens. Consequently, a significant need exists for chemotherapeutic agents, which are not only clinically efficacious, but have acceptable side-effect profiles. Paclitaxel poliglumex (PPX) is a recently developed taxane in which paclitaxel is conjugated to poly(l-glutamic acid), which renders it water soluble, reduces hypersensitivity reactions and preferentially targets it to the tumor. AREAS COVERED: This review covers pre-clinical pharmacokinetic data and key Phase I and II clinical trial results in ovarian cancer. EXPERT OPINION: While PPX is active in ovarian cancer, it is unclear at present whether it offers significant benefit in terms of its side-effect profile or outcomes over a standard taxane-based regimen as first-line therapy, or what role it will have in maintenance therapy as studies are ongoing.
    [Abstract] [Full Text] [Related] [New Search]